Bispecific Anti ErbB1 / Anti c Met Antibodies
First Claim
1. A bispecific antibody that specifically binds to human ErbB-1 and human c-Met comprising a first antigen-binding site that specifically binds to human ErbB-1 and a second antigen-binding site that specifically binds to human c-Met, wherein the bispecific antibody causes an increase in internalization of c-Met on OVCAR-8 cells of no more than 15% when measured after 2 hours of OVCAR-8 cell-antibody incubation as measured by a flow cytometry assay as compared to internalization of c-Met on OVCAR-8 cells in the absence of the bispecific antibody.
4 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to bispecific antibodies against human ErbB-1 and against human c-Met, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.
-
Citations
13 Claims
- 1. A bispecific antibody that specifically binds to human ErbB-1 and human c-Met comprising a first antigen-binding site that specifically binds to human ErbB-1 and a second antigen-binding site that specifically binds to human c-Met, wherein the bispecific antibody causes an increase in internalization of c-Met on OVCAR-8 cells of no more than 15% when measured after 2 hours of OVCAR-8 cell-antibody incubation as measured by a flow cytometry assay as compared to internalization of c-Met on OVCAR-8 cells in the absence of the bispecific antibody.
-
4. A bispecific antibody that specifically binds to human ErbB-1 and human c-Met comprising a first antigen-binding site that specifically binds to human ErbB-1 and a second antigen-binding site that specifically binds to human c-Met, wherein
i) the first antigen-binding site comprises in the heavy chain variable domain a CDR3 region with the amino acid sequence of SEQ ID NO: - 17, a CDR2H region with the amino acid sequence of SEQ ID NO;
18, and a CDR1H region with the amino acid sequence of SEQ ID NO;
19, and in the light chain variable domain a CDR3L region with the amino acid sequence of SEQ ID NO;
20, a CDR2L region with the amino acid sequence of SEQ ID NO;
21, and a CDR1L region with the amino acid sequence of SEQ ID NO;
58 or a CDR1L region with the amino acid sequence of SEQ ID NO;
22; andthe second antigen-binding site comprises in the heavy chain variable domain a CDR3H region with the amino acid sequence of SEQ ID NO;
30, a CDR2H region with the amino acid sequence of, SEQ ID NO;
31, and a CDR1H region with the amino acid sequence of SEQ ID NO;
32, and in the light chain variable domain a CDR3L region with the amino acid sequence of SEQ ID NO;
33, a CDR2L region with the amino acid sequence of SEQ ID NO;
34, and a CDR1L region with the amino acid sequence of SEQ ID NO;
35.ii) the first antigen-binding site comprises in the heavy chain variable domain a CDR3H region with the amino acid sequence of SEQ ID NO;
23, a CDR2H region with the amino acid sequence of SEQ ID NO;
24, and a CDR1H region with the amino acid sequence of SEQ ID NO;
25, and in the light chain variable domain a CDR3L region with the amino acid sequence of SEQ ID NO;
26, a CDR2L region with the amino acid sequence of SEQ ID NO;
27, and a CDR1L region with the amino acid sequence of SEQ ID NO;
28 or a CDR1L region with the amino acid sequence of SEQ ID NO;
29; andthe second antigen-binding site comprises in the heavy chain variable domain a CDR3H region with the amino acid sequence of SEQ ID NO;
30, a CDR2H region with the amino acid sequence of, SEQ ID NO;
31, and a CDR1H region with the amino acid sequence of SEQ ID NO;
32, and in the light chain variable domain a CDR3L region with the amino acid sequence of SEQ ID NO;
33, a CDR2L region with the amino acid sequence of SEQ ID NO;
34, and a CDR1L region with the amino acid sequence of SEQ ID NO;
35. - View Dependent Claims (5, 7, 9, 11, 13)
- 17, a CDR2H region with the amino acid sequence of SEQ ID NO;
Specification